Mature T-cell tumors, such as non-Hodgkin T-cell lymphoma, are highly invasive and drug-resistant, and patients often have a poor prognosis. Recently, "Nature" series of two articles published a new i...
A study conducted at the Los Angeles Children ’s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).This study (a 20-year quantitative...
Yesterday, the US FDA announced the approval of Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with chemotherapy for patients with previously treated stage III...
According to the results of a 5-year follow-up of the key PACE trial published in the Journal of Hematology, panatinib (Ponatinib, Iclusig) has maintained long-lasting in severely treated patients wit...
New Cleveland Clinic research shows for the first time that FDA-approved ibrutinib (ibrutinib) for lymphoma and leukemia may also help treat the most common and deadly brain tumors, and may one day be...
Bosutinib is a Src / Abl dual tyrosine kinase inhibitor approved for the treatment of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), or resistant or intolerant to previous trea...
The latest research found that some statins can improve the efficacy of chemotherapy drugs used to treat blood cancer in mouse models. Statins are drugs that treat patients with reduced fat in the blo...
Bone marrow fibrosis is a rare chronic disease of bone marrow hematopoietic cells. They benefit from JAK2 inhibitor drugs: symptom relief, prolonged survival, and improved quality of life. However, t...
On June 8 , the US FDA approved Venetoclax ( VENCLEXTA , AbbVie Inc. and Genentech Inc. ) for patients with chronic lymphocytic leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ), with or without ...
On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later, the US FDA approved pembrolizumab (Keytrud...